[Bora] Acquires CDMO Operating Assets Through Newly Established Subsidiary Bora Biologics USA LLC
Bora is acquiring CDMO operating assets in Maryland, USA, for USD 122.5 million through its newly established subsidiary, Bora Biologics USA LLC. This strategic move aims to accelerate the expansion of its commercial large-scale CDMO business in North America. MacroGenics, Inc. is the seller.
📋 Article Processing Timeline
- 📰 Published: May 11, 2026 at 09:00
- 🔍 Collected: May 13, 2026 at 08:00 (47h 0m after Published)
- 🤖 AI Analyzed: May 13, 2026 at 13:17 (5h 17m after Collected)
1. Name and nature of the target object (e.g., land located in Taichung City, North District, Section XX, Lot XX, etc.): CDMO operating assets located in Maryland, USA, including production equipment, employees, and contracted development and production business. 2. Date of occurrence: 115/5/11~115/5/11. 3. Date of board approval: May 11, 115 (Republic of China calendar year). 4. Other approval dates: Not applicable. 5. Transaction unit quantity (e.g., XX square meters, equivalent to XX ping), price per unit, and total transaction amount: Transaction unit quantity: A batch of operating assets (including operating equipment, employees, and approximately 139,600 square feet of leased factory space). Transaction amount: USD 122,500,000 (approximately NTD 3,847,112,500). 6. Transaction counterparty and its relationship with the company (if the counterparty is an individual and not an affiliate of the company, their name may be omitted): MacroGenics, Inc. (NASDAQ:MGNX); Not an affiliate. 7. If the counterparty is an affiliate, also announce the reason for selecting the affiliate as the counterparty, the previous owner, the relationship between the previous owner, the company, and the counterparty, the date of the previous transfer, and the transfer amount: Not applicable. 8. If the owner of the transaction target in the last five years was an affiliate of the company, also announce the date, price, and relationship with the company at the time of the transaction: Not applicable. 9. Estimated profit (or loss) from disposal (not applicable for asset acquirers) (deferred items should be listed to explain recognition status): Not applicable. 10. Delivery or payment terms (including payment period and amount), contract restrictions, and other important agreed matters: As per the asset purchase agreement, the company's wholly-owned subsidiary Bora Biologics USA LLC will acquire the CDMO operating assets through cash consideration. Actual handover progress depends on local regulatory conditions. The Chairman is authorized to handle payment matters for this transaction. 11. Method of transaction decision (e.g., bidding, price comparison, or negotiation), basis for price determination, and decision-making unit: Price determination: Based on bids and negotiations with reference to the valuation report from the accounting firm and market conditions. Decision-making unit: Board of Directors. 12. Name of professional appraisal firm or company and its appraised amount: Professional appraisal firm: LI BEN TAIWAN CPA Firm. Appraised amount range: USD 119,877 thousand ~ USD 135,627 thousand. 13. Name of professional appraiser: CHOU CHIH-HSIEN. 14. Appraiser's practice certificate number: Taiwan Financial and Securities Registration No. 3209. 15. Whether the appraisal report is for a limited price, specific price, or special price: No or not applicable. 16. Whether the appraisal report has not yet been obtained: No or not applicable. 17. Reason for not obtaining the appraisal report: Not applicable. 18. If there is a significant difference in the appraisal results, the reason for the difference and the accountant's opinion: Not applicable. 19. Name of accounting firm: Not applicable. 20. Name of accountant: Not applicable. 21. Accountant's practice certificate number: Not applicable. 22. Broker and brokerage fee: Not applicable. 23. Specific purpose or use of the acquisition or disposal: To accelerate the expansion of the North American indigenous commercial large-scale CDMO business. 24. Opinion of dissenting directors for this transaction: None. 25. Is this transaction a related party transaction: No. 26. Date of supervisor's approval or audit committee's consent: May 11, 115 (Republic of China calendar year). 27. Did this transaction involve the acquisition of real estate or its usage rights from a related party: No. 28. Price appraised according to Article 16 of the "Regulations Governing Acquisitions or Disposals of Assets by Public Companies": Not applicable. 29. If the price appraised according to the preceding paragraph is lower than the transaction price, the price appraised according to Article 17 of the same Regulations: Not applicable. 30. Date of previous announcement of material information on the same event: Not applicable. 31. Other descriptions: None. Keywords: Material Information